Cerevel Therapeutics Holdings, Inc. - Common Stock (NQ:CERE)

44.96 UNCHANGED

Last Price Updated: 4:15 PM EDT, Jul 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cerevel Therapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Top 5 Health Care Stocks That Should Keep You Up At Night ↗

May 23, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗

May 04, 2023

Via Benzinga

Analyst Expectations for Cerevel Therapeutics Hldg's Future ↗

May 04, 2023

Via Benzinga

What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg ↗

May 04, 2023

Via Benzinga

Cerevel Therapeutics Hldg: Q1 Earnings Insights ↗

May 03, 2023

Via Benzinga

Where Cerevel Therapeutics Hldg Stands With Analysts ↗

April 03, 2023

Via Benzinga

Analyst Expectations for Cerevel Therapeutics Hldg's Future ↗

March 09, 2023

Via Benzinga

Data Shows Cerevel's Emraclidine Does Not Induce High Blood Pressure In Schizophrenia Patients ↗

December 19, 2022

Via Benzinga

What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg ↗

December 06, 2022

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023 ↗

April 10, 2023

Via Benzinga

Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket ↗

March 01, 2023

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

Via Benzinga

Analyst Ratings for Cerevel Therapeutics Hldg ↗

September 13, 2022

Analysts have provided the following ratings for Cerevel Therapeutics Hldg (NASDAQ:CERE) within the last quarter:

Via Benzinga

Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why ↗

August 23, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023 ↗

March 17, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2023 ↗

February 23, 2023

Via Benzinga

Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 22, 2023

Gainers Windtree Therapeutics Inc (NASDAQ: WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous...

Via Benzinga

Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing' ↗

February 03, 2023

Via Benzinga

Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday ↗

December 19, 2022

U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

December 19, 2022

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Via Benzinga

What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg ↗

November 09, 2022

Over the past 3 months, 8 analysts have published their opinion on Cerevel Therapeutics Hldg (NASDAQ:CERE) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Tyson Foods To $61? Plus Needham Slashes PT On This Stock By 33% ↗

November 09, 2022

B of A Securities cut the price target on Tyson Foods, Inc. (NYSE: TSN) from $73 to $61. Tyson Foods shares fell 1.9% to $66.44 in pre-market trading.

Via Benzinga

Why Cerevel Therapeutics Holdings Shares Are Nosediving ↗

November 08, 2022

Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 6.42% to $25.37 during Tuesday's session after the company reported worse-than-expected third-quarter EPS results and filed...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg ↗

October 20, 2022

Cerevel Therapeutics Hldg (NASDAQ:CERE) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022 ↗

October 20, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022 ↗

September 29, 2022

Upgrades

Via Benzinga

Analyst Ratings for Cerevel Therapeutics Hldg ↗

September 29, 2022

Over the past 3 months, 8 analysts have published their opinion on Cerevel Therapeutics Hldg (NASDAQ:CERE) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022 ↗

September 26, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022 ↗

September 13, 2022

Upgrades See all analyst ratings upgrades.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.